BRD2 and infectious disease: Nevertheless, we cannot be complacent, since new emerging and re-emerging infectious disease agents are on the horizon and a continuing add-on strategy with more and more specific NAT and/or serological assays for these upcoming infectious agents is unlikely to be sustainable in the long run.